Gw Pharmaceuticals Plc Stock Current Asset
GW Pharmaceuticals Plc fundamentals help investors to digest information that contributes to GW Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of GWPH Stock. The fundamental analysis module provides a way to measure GW Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GW Pharmaceuticals stock.
GWPH |
GW Pharmaceuticals Plc Company Current Asset Analysis
GW Pharmaceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current GW Pharmaceuticals Current Asset | 404.52 M |
Most of GW Pharmaceuticals' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GW Pharmaceuticals Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, GW Pharmaceuticals Plc has a Current Asset of 404.52 M. This is 81.2% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current asset for all United States stocks is 95.67% higher than that of the company.
GWPH Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GW Pharmaceuticals' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GW Pharmaceuticals could also be used in its relative valuation, which is a method of valuing GW Pharmaceuticals by comparing valuation metrics of similar companies.GW Pharmaceuticals is currently under evaluation in current asset category among related companies.
GWPH Fundamentals
| Return On Equity | -7.92 | |||
| Return On Asset | -3.55 | |||
| Profit Margin | (11.03) % | |||
| Operating Margin | (9.82) % | |||
| Current Valuation | 6.42 B | |||
| Shares Outstanding | 31.54 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 80.35 % | |||
| Number Of Shares Shorted | 693.73 K | |||
| Price To Earning | 126.70 X | |||
| Price To Book | 9.24 X | |||
| Price To Sales | 12.92 X | |||
| Revenue | 527.2 M | |||
| Gross Profit | 489.67 M | |||
| EBITDA | (39.01 M) | |||
| Net Income | (58.13 M) | |||
| Cash And Equivalents | 486.75 M | |||
| Cash Per Share | 15.53 X | |||
| Total Debt | 43.64 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 4.57 X | |||
| Book Value Per Share | 23.70 X | |||
| Cash Flow From Operations | (27.39 M) | |||
| Short Ratio | 1.15 X | |||
| Earnings Per Share | (1.86) X | |||
| Price To Earnings To Growth | 3.61 X | |||
| Number Of Employees | 1.16 K | |||
| Beta | 1.67 | |||
| Market Capitalization | 6.81 B | |||
| Total Asset | 453.18 M | |||
| Retained Earnings | (813.7 M) | |||
| Working Capital | 369.57 M | |||
| Current Asset | 404.52 M | |||
| Current Liabilities | 34.95 M | |||
| Z Score | 93.2 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |